Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
What’s Your Call?
Collective community sentiment on Kabra Drugs Ltd
Your Vote -
Buy
33.33%
Hold
0.00%
Sell
66.67%
33.33%
3 users have voted
Option Chain
Analyzes market sentiment, predicts Kabra Drugs Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Kabra Drugs Ltd. - Reg. 34 (1) Annual Report.
-
Kabra Drugs Ltd. - Book Closure And Schedule Of Events For E-Voting.
-
Kabra Drugs Ltd. - Appointment Of Secretarial Auditor
-
Kabra Drugs Ltd. - Appointment Of Internal Auditor
-
Kabra Drugs Ltd. - Board Meeting Outcome for Outcome Of Board Meeting Held On 02 Nd September 2025, As Per Regulation 30 Of S
-
Kabra Drugs Ltd. - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations
-
Kabra Drugs Ltd. - Financial Results For The Quarter Ended June 30, 2025 Under Regulation 33 Of SEBI (Listing Obligations & D
-
Kabra Drugs Ltd. - Board Meeting Outcome for Outcome Of Board Meeting Held On 14Th August 2025, As Per Regulation 30 Of\r\nSE
-
Kabra Drugs Ltd. - Board Meeting Intimation for Intimation Of Board Meeting
-
Kabra Drugs Ltd. - Board Meeting Outcome for Outcome Of The Board Meeting And Disclosure Under Regulation 30 Of SEBI (Listing
-
Kabra Drugs Ltd. - Board Meeting Intimation for Board Meeting
-
Kabra Drugs Ltd. has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2025
-
Kabra Drugs Ltd. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Key fundamentals
Evaluate the intrinsic value of Kabra Drugs Ltd stock
| Name | March-24 | March-23 | March-22 | March-21 | March-20 |
|---|---|---|---|---|---|
| Assets | 2.7913 | 0.6508 | 0.6326 | 0.6927 | 0.6247 |
| Liabilities | 2.7913 | 0.6508 | 0.6326 | 0.6927 | 0.6247 |
| Equity | 4.3886 | 4.3886 | 4.3886 | 4.3886 | 4.3886 |
| Gross Profit | -0.736 | -0.3442 | -0.1754 | -0.1487 | -0.0272 |
| Net Profit | -0.736 | -0.3379 | -0.1853 | -0.18 | -0.0595 |
| Cash From Operating Activities | -0.2085 | -0.3544 | -0.1338 | -0.2491 | -0.046 |
| NPM(%) | 0 | 0 | 0 | 0 | -264.09 |
| Revenue | 0 | 0 | 0 | 0 | 0.0225 |
| Expenses | 0.736 | 0.3442 | 0.1754 | 0.1487 | 0.0498 |
| ROE(%) | -2.98 | -1.37 | -0.75 | -0.73 | -0.24 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Kabra Drugs Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 801.00 | -1.01 | 72.72 | 11.07 | 301.39 | 0.62 |
| Lotus Eye Hospital and Institute Ltd | 119.50 | -2.85 | 389.61 | 40.32 | 3.55 | 0.00 |
| Bharat Immunological and Biologicals Corporation Ltd | 22.01 | 0.23 | 0.00 | 83.73 | -39.50 | 0.00 |
| Astec Lifesciences Ltd | 823.00 | -1.44 | 0.00 | 38.03 | -604.77 | 0.00 |
Company Info
The company Kabra Drugs Ltd was originally incorporated as Pvt. Ltd company on 22.8.1989 and was subsequently converted into a Public Ltd Company on 1.04.1992. The company is coming out with a public issue on 03.03.93 to part finance the expansion project to manufacture pharmaceutical formulations being set up. The first phase of the project i.e,Ether section has already commenced commercial production. The implementation of second phase involving manufacture of injectables is nearing compoletion and the commercial production is likely to be commenced by June 1993. The implementation of the third and last phase has also started. 2014 -Kabra Drugs appointed M/s. M. Maheshwari & Associates, Practicing Company Secretary for Secretarial Audit.
The company Kabra Drugs Ltd was originally incorporated as Pvt. Ltd company on 22.8.1989 and was subsequently converted into a Public Ltd Company on 1.04.1992. The company is coming out with a public issue on 03.03.93 to part finance the expansion project to manufacture pharmaceutical formulations being set up. The first phase of the project i.e,Ether section has already commenced commercial production. The implementation of second phase involving manufacture of injectables is nearing compoletion and the commercial production is likely to be commenced by June 1993. The implementation of the third and last phase has also started. 2014 -Kabra Drugs appointed M/s. M. Maheshwari & Associates, Practicing Company Secretary for Secretarial Audit.
Read More
Parent Organisation
Kabra Drugs Ltd.
Founded
22/08/1989
Managing Director
Mr.N Aravind
NSE Symbol
FAQ
The current price of Kabra Drugs Ltd is
The 52-week high for Kabra Drugs Ltd is
The market capitalization of Kabra Drugs Ltd is currently This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Kabra Drugs Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Kabra Drugs Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Kabra Drugs Ltd shares.
The CEO of Kabra Drugs Ltd is Mr.N Aravind, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
